Insulet Corp
Suletud
SektorTervishoid
145.05 1.14
Ülevaade
Aktsiahinna muutus
24h
Min
141.4
Max
146.11
Sissetulek | -11M 91M |
|---|---|
Müük | -22M 762M |
P/E Sektori keskmine | 34.612 49.712 |
Aktsiakasum | 1.3 |
Kasumimarginaal | 11.96 |
Töötajad | 5,400 |
EBITDA | -23M 154M |
Soovitused | Tugev "osta" hinnang |
|---|---|
12 kuu keskmine prognoos | +59.8% upside |
Järgmine tulemuste avaldamine | 6. aug 2026 |
|---|
Turukapital | -1.6B 10B |
|---|---|
Eelmine avamishind | 143.91 |
Eelmine sulgemishind | 145.05 |
Uudiste sentiment
By Acuity
61%
39%
269 / 342 Pingereas Healthcare
Insulet Corp Graafik
Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.
Ettevõttest Insulet Corp
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.